AlphaValue’s analyst covering MindMaze Therapeutics, the former Relief Therapeutics that now trades at a market capitalisation of just over CHF 30 million, has lowered the Swiss‑penny stock’s six‑month price target to CHF 1.19 from CHF 1.37. The target was previously CHF 1.78 when the stock was around CHF 0.34 per share in late April. Despite the reduction, the analyst retains a buy recommendation, noting that the firm still requires additional financing rounds to reach breakeven, which could dilute existing shareholders.
MindMaze has been the worst‑performing component of the Swiss Performance Index (SPI) this year, having lost more than 90 % of its value since the start of January. Only two analysts are known to follow the stock, AlphaValue being one of them.
In a separate note, Bank of America pharma analyst Sachin Jain downplays the impact of Novartis’s recent setback with its heart‑drug candidate Pelacarsen. Jain estimates that the product‑related disappointment reduces the net present value of Novartis shares by only a low single‑digit percentage and argues that the study results are of limited relevance to the stock’s trajectory. He continues to rate Novartis as a buy with a target price of CHF 150, the highest level he has recorded for the company.
Novartis shares had slipped in New York trading after the Pelacarsen news, but the defensive stance from the London‑based analyst may help limit further losses on the Swiss market. Jain also highlighted upcoming data on the multiple‑sclerosis drug Remibrutinib, which remains a focus for the company.
Both analysts’ comments underscore the divergent risk profiles within the Swiss pharma sector: MindMaze remains a highly speculative, low‑cap stock requiring fresh capital, while Novartis, a large‑cap SMI heavyweight, is viewed as resilient despite isolated product setbacks.
